# US 2016/0354478 A1 · Amine pegylation methods for the preparation of site-specific protein conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354478 A1
- Document ID: US20160354478A1
- Status: Published application
- Kind: A1
- Application number: 15/158,898
- Filed: 2016-05-19
- Published: 2016-12-08
- Earliest claimed: 2015-06-04
- Assignees: AntriaBio, Inc.
- Applicants: AntriaBio, Inc.
- Inventors: Mary S. Rosendahl; Sankaram B. Mantripragada
- Web page: https://patentgrep.com/patent/US20160354478A1

## CPC

- A61K 38/26: Glucagons
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 38/28: Insulins
- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Examples include a method of making a protein-PEG conjugate. The method may include providing an aqueous protein solution. The aqueous protein solution may include a protein, a pH buffer, and a chelating agent. The chelating agent may be chosen from the group consisting of an aminopolycarboxylic acid, a hydroxyaminocarboxylic acid, an N-substituted glycine, 2-(2-amino-2-oxocthyl) aminoethane sulfonic acid (BES), and deferoxamine (DEF). The method may also include introducing sodium cyanoborohydride and a methoxy polyethylene glycol aldehyde to the aqueous protein solution. The sodium cyanoborohydride in the methoxy polyethylene glycol aldehyde may have a molar ratio ranging from about 5:1 to about 1.5:1. The method may further include reacting the methoxy polyethylene glycol aldehyde with the protein to form the protein-PEG conjugate. The pH buffer may maintain a pH of the aqueous protein solution ranging from 4.0 to 4.4 during the reaction.

## Claims

### Claim 1

A method of making a protein-PEG conjugate, the method comprising:
providing an aqueous protein solution comprising a protein, a pH buffer, and a chelating agent, wherein the chelating agent is chosen from the group consisting of an aminopolycarboxylic acid, a hydroxyaminocarboxylic acid, an N-substituted glycine, 2-(2-amino-2-oxocthyl) aminoethane sulfonic acid (BES), and deferoxamine (DEF);
introducing boron-containing reducing agent and a methoxy polyethylene glycol aldehyde to the aqueous protein solution, wherein the boron-containing reducing agent and methoxy polyethylene glycol aldehyde have a molar ratio ranging from about 25:1 to about 1.5:1; and
reacting the methoxy polyethylene glycol aldehyde with the protein to form the protein-PEG conjugate, wherein the pH buffer maintains a pH of the aqueous protein solution ranging from 4.0 to 6.0 during the reaction.

### Claim 2 (depends on 1)

The method of claim 1, wherein the boron-containing reducing agent is selected from the group consisting of sodium cyanoborohydride, dimethylamine borane, trimethylamine borane, 2-methyl pyridine borane, sodium triacetoxyborohydride, triethylamine borane, morpholine borane, tert butylamine borane, and 5-ethyl-2-methyl-pyridine borane.

### Claim 3 (depends on 1)

The method of claim 1, wherein the boron-containing reducing agent is 2-methyl pyridine borane.

### Claim 4 (depends on 1)

The method of claim 1, wherein the reaction of the methoxy polyethylene glycol aldehyde with the protein yields a site-specific mono-PEGylated protein-PEG conjugate at greater than 75% of all protein-PEG conjugates produced.

### Claim 5 (depends on 1)

The method of claim 1, wherein the protein is chosen from the group consisting of insulin, parathyroid hormone, a fragment of parathyroid hormone, growth hormone, glucagon-like peptide-1, enfuvirtide, and octreotide.

### Claim 6 (depends on 4)

The method of claim 4, wherein the protein comprises insulin and the site-specific mono-PEGylated protein-PEG conjugate comprises PEG-PheB1-insulin conjugate.

### Claim 7 (depends on 1)

The method of claim 1, wherein the protein comprises a fragment of parathyroid hormone.

### Claim 8 (depends on 1)

The method of claim 1, wherein the pH buffer comprises an inorganic salt of phosphoric acid.

### Claim 9 (depends on 1)

The method of claim 1, wherein the aminopolycarboxylic acid is chosen from the group consisting of ethylenediaminetetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA), nitrilotriacetic acid (NTA), N-2-acetamido-2-iminodiacetic acid (ADA), bis(aminoethyl)glycolether, N,N,N′,N′-tetraacetic acid (EGTA), trans-diaminocyclohexane tetraacetic acid (DCTA), glutamic acid, and aspartic acid.

### Claim 10 (depends on 5)

The method of claim 5, wherein the aminopolycarboxylic acid is ethylenediaminetetraacetic acid (EDTA).

### Claim 11 (depends on 1)

The method of claim 1, wherein the hydroxyaminocarboxylic acid is chosen from the group consisting of N-hydroxyethyliminodiacetic acid (HIMDA), N,N-bis-hydroxyethylglycine, and N-trishydroxymethylmethyl) glycine.

### Claim 12 (depends on 1)

The method of claim 1, wherein the N-substituted glycine comprises glycylglycine.

### Claim 13

A method of making an insulin-PEG conjugate, the method comprising:
providing an aqueous insulin solution comprising an insulin, a pH buffer, an organic solvent, and a chelating agent comprising ethylenediaminetetraacetic acid (EDTA);
introducing a boron-containing reducing agent and a methoxy polyethylene glycol aldehyde to the aqueous insulin solution, wherein the boron-containing reducing agent and methoxy polyethylene glycol aldehyde have a molar ratio ranging from about 25:1 to about 1.5:1; and
reacting the methoxy polyethylene glycol aldehyde with the insulin to form the insulin-PEG conjugate, wherein the pH buffer maintains a pH of the aqueous insulin solution in a range from 4.0 to 6.0 during the reaction, and wherein the reaction of the methoxy polyethylene glycol aldehyde with the insulin yields a PEG-PheB1-insulin conjugate at greater than 75% of all insulin-PEG conjugates produced.

### Claim 14 (depends on 13)

The method of claim 13, wherein the boron-containing reducing agent is selected from the group consisting of sodium cyanoborohydride, dimethylamine borane, trimethylamine borane, 2-methyl pyridine borane, sodium triacetoxyborohydride, triethylamine borane, morpholine borane, tert butylamine borane, and 5-ethyl-2-methyl-pyridine borane.

### Claim 15 (depends on 13)

The method of claim 13, wherein the boron-containing reducing agent is 2-methyl pyridine borane.

### Claim 16 (depends on 13)

The method of claim 13, wherein the methoxy polyethylene glycol aldehyde and the insulin have a molar ratio of about 10:1 to about 1:1 when the reaction starts.

### Claim 17 (depends on 13)

The method of claim 13, wherein the boron-containing reducing agent and methoxy polyethylene glycol aldehyde have a molar ratio ranging from about 22:1 to about 5.5:1.

### Claim 18 (depends on 13)

The method of claim 13, wherein the organic solvent is chosen from the group consisting of ethanol, methanol, dimethyl sulfoxide (DMSO), dioxane, acetonitrile, dimethylformamide (DMF), and N-methylpyrrolidone (NMP).

### Claim 19 (depends on 13)

The method of claim 13, wherein the organic solvent is dioxane.

### Claim 20 (depends on 13)

The method of claim 13, wherein the pH of the aqueous insulin solution is 5.0 during the reaction.

### Claim 21 (depends on 13)

The method of claim 13, wherein the insulin comprises human insulin.

### Claim 22 (depends on 13)

The method of claim 13, wherein the reaction of the methoxy polyethylene glycol aldehyde with the insulin yields the PEG-PheB1-insulin conjugate at 75% to 85% of all insulin-PEG conjugates produced.

### Claim 23

A method of making controlled-release microspheres containing a protein-PEG conjugate, the method comprising:
providing an aqueous protein solution comprising a protein, a pH buffer, and a chelating agent, wherein the chelating agent is chosen from the group consisting of an aminopolycarboxylic acid, a hydroxyaminocarboxylic acid, an N-substituted glycine, 2-(2-amino-2-oxocthyl) aminoethane sulfonic acid (BES), and deferoxamine (DEF);
introducing a boron-containing reducing agent and a methoxy polyethylene glycol aldehyde to the aqueous protein solution, wherein the boron-containing reducing agent and methoxy polyethylene glycol have a molar ratio ranging from about 25:1 to about 1.5:1;
reacting the methoxy polyethylene glycol aldehyde with the protein to form the protein-PEG conjugate, wherein the pH buffer maintains a pH of the aqueous protein solution ranging from 4.0 to 6.0 during the reaction;
mixing the protein-PEG conjugate in an organic solvent with a biodegradable polymer to form a mixture;
emulsifying the mixture of the protein-PEG conjugate and the biodegradable polymer in an aqueous solution to form an emulsified mixture; and
hardening the emulsified mixture of the protein-PEG conjugate and the biodegradable polymer into the controlled-release microspheres.

### Claim 24 (depends on 23)

The method of claim 23, wherein the boron-containing reducing agent is selected from the group consisting of sodium cyanoborohydride, dimethylamine borane, trimethylamine borane, 2-methyl pyridine borane, sodium triacetoxyborohydride, triethylamine borane, morpholine borane, tert butylamine borane, and 5-ethyl-2-methyl-pyridine borane.

### Claim 25 (depends on 23)

The method of claim 23, wherein the boron-containing reducing agent is 2-methyl pyridine borane.

### Claim 26 (depends on 23)

The method of claim 23, wherein the protein comprises insulin, the protein-PEG conjugate is a site-specific mono-PEGylated protein-PEG conjugate, and the site-specific mono-PEGylated protein-PEG conjugate comprises PEG-PheB1-insulin conjugate.

### Claim 27 (depends on 26)

The method of claim 26, wherein the PEG-PheB1-insulin conjugate has a yield of 75% to 85% of all insulin-PEG conjugates produced.

### Claim 28 (depends on 23)

The method of claim 23, wherein the pH buffer comprises an inorganic salt of phosphoric acid.

### Claim 29 (depends on 23)

The method of claim 23, wherein the chelating agent comprises ethylenediaminetetraacetic acid (EDTA).

### Claim 30 (depends on 23)

The method of claim 23, wherein the boron-containing reducing agent and methoxy polyethylene glycol aldehyde have a molar ratio ranging from about 25:1 to about 5:1.

### Claim 31 (depends on 23)

The method of claim 23, wherein the pH of the aqueous protein solution is 5.0 during the reaction.

### Claim 32 (depends on 23)

The method of claim 23, wherein the organic solvent comprises methylene chloride.

### Claim 33 (depends on 23)

The method of claim 23, wherein the biodegradable polymer is chosen from the group consisting of a polylactide; a polyglycolide; a poly(d,l-lactide-co-glycolide); a polycaprolactone; a polyorthoester; a copolymer of a polyester and a polyether; and a copolymer of polylactide and polyethylene glycol.

### Claim 34 (depends on 23)

The method of claim 23, wherein the biodegradable polymer comprises poly(d,l-lactide-co-glycolide).
